We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Orifarm UK Ltd has informed the MHRA that the Patient Information Leaflet (PIL) in one batch of Buccolam 10mg Oromucosal solution has missing information regarding having to break the seal on the inner container before use.
A summary of letters and drug alerts recently sent to healthcare professionals.
A short course (3 to 7 days) may be used with caution in certain patients with an eGFR of 30 to 44 ml/min/1.73m2
Local decision-making around fluoridation of drinking water: consultation responses.
First published during the 2010 to 2015 Conservative and Liberal Democrat coalition government
The Medicines and Healthcare products Regulatory Agency (MHRA) responses to freedom of information (FOI) requests for week commencing 21 February 2022
In July 2014, Public Health England (PHE) received a request in relation to water fluoridation in Southampton.
First published during the 2022 to 2024 Sunak Conservative government
Informal note on Defra’s position on Formaldehyde (Formalin)
Disabling, long-lasting or potentially irreversible adverse reactions affecting musculoskeletal and nervous systems have been reported very rarely with fluoroquinolone antibiotics. Fluoroquinolone treatment should be discontinued at the first signs of a serious adverse reaction, including tendon pain or inflammation.
The Smile4Life programme aims to reduce tooth decay in children, laying a solid foundation for their good oral health throughout life.
Letters were sent about cladribine (Litak and Leustat), radium-223-dichloride (Xofigo▼), and ERWINASE.
Product defect recall alert for Ornicure 150mg/g doxycycline powder for oral solution by Versele-Laga.
Approval of biocides withdrawn from 16 February
Avoid treatment with febuxostat in patients with pre-existing major cardiovascular disease (for example, myocardial infarction, stroke, or unstable angina), unless no other therapy options are appropriate. Findings from a phase 4 clinical study (the CARES study) in patients with gout...
First published during the 2016 to 2019 May Conservative government
£880,000 of Innovate UK funding speeds development of 3D nanofibre filtration process for more cost-effective manufacture of enzymes
Healthy Teeth, Happy Smiles! is an early intervention programme from birth to improve the oral health of preschool children.
Topical oral salicylate gels are no longer indicated for people younger than 16 years for pain associated with infant teething, orthodontic devices, cold sores, or mouth ulcers.
Medicines have been taken out of the regulated medicines’ supply chain during distribution. The products have been parallel imported into the UK by B & S Healthcare from Italy and have been re-labelled in B & S Healthcare livery.
FDC Pharma are recalling batch 087B087 due to an out of specification result for an unknown impurity during stability testing. (EL(18)A/08)
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).